XML 43 R20.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Note 13 - Income Taxes | 12 Months Ended
--- | ---
Dec. 31, 2021
Notes to Financial Statements |
Income Tax Disclosure [Text Block] | Note 13 — Income Taxes The Company has incurred net losses since inception and, consequently, has not recorded any U.S. Federal and state income tax expense or benefit. The components of loss before provision for income taxes were as follows:
|  | Years Ended December 31, |
|  | 2021 |  |  | 2020 |
Domestic |  | $ | (159,632 | ) |  | $ | (176,613 | )
Foreign |  |  | (22,177 | ) |  |  | (6,201 | )
Loss before provision for income taxes |  | $ | (181,809 | ) |  | $ | (182,814 | )
The differences between the Company’s effective tax rate and the statutory tax rate in 2021, 2020, and 2019, are as follows:
|  | 2021 |  |  | 2020 |  |  | 2019 |
Income tax benefit at federal statutory rate (21% for 2021, 2020 and 2019) |  | $ | (38,175 | ) |  | $ | (38,391 | ) |  | $ | (22,868 | )
State and local income taxes net of federal tax benefit |  |  | (2,288 | ) |  |  | (2,544 | ) |  |  | (1,591 | )
Permanent items |  |  | (1,343 | ) |  |  | 774 |  |  |  | 691 |
Rate change |  |  | − |  |  |  | (82 | ) |  |  | 625 |
Expiration of attribute carryforwards |  |  | (1,057 | ) |  |  | 3,774 |  |  |  | 3,976 |
Research and development tax credits |  |  | (5,994 | ) |  |  | (4,080 | ) |  |  | (4,938 | )
Foreign rate differential |  |  | 1,940 |  |  |  | 542 |  |  |  | - |
Other |  |  | 1,216 |  |  |  | 1,456 |  |  |  | 281 |
Change in valuation allowance |  |  | 47,954 |  |  |  | 38,551 |  |  |  | 23,824 |
Income tax expense |  | $ | 2,253 |  |  | $ | − |  |  | $ | − |
The Company recognizes the impact of a tax position in its financial statements if it is more likely than not that the position will be sustained on audit based on the technical merits of the position. The Company has concluded that it has an uncertain tax position pertaining to its research and development and orphan drug credit carryforwards. The Company has established these credits based on information and calculations it believes are appropriate and the best estimate of the underlying credit. Any changes to the Company’s unrecognized tax benefits are offset by an adjustment to the valuation allowance and there would be no impact on the Company’s financial statements. The Company does not expect its unrecognized tax benefits to change significantly over the next 12 months. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:
|  | 2021 |  |  | 2020 |
Balance at January 1, |  | $ | 8,230 |  |  | $ | 7,210 |
Additions to current period tax positions |  |  | 1,499 |  |  |  | 1,020 |
Balance at December 31, |  | $ | 9,729 |  |  | $ | 8,230 |
The Company’s ability to utilize the net operating loss and tax credit carryforwards in the future may be subject to substantial restrictions in the event of past or future ownership changes as defined in Section 382 of the Internal Revenue Code of 1986, as amended and similar state tax law. Significant components of the Company’s deferred tax assets and liabilities are as follows:
|  | 2021 |  |  | 2020 |
Deferred tax assets: |  |  |  |  |  |  |  |
Net federal and state operating losses |  | $ | 113,649 |  |  | $ | 159,939 |
Research and development credits |  |  | 71,197 |  |  |  | 66,331 |
Royalty income |  |  | 106,007 |  |  |  | 28,034 |
Stock-based compensation |  |  | 14,512 |  |  |  | 10,732 |
Capitalized R&D |  |  | 8,997 |  |  |  | − |
Leasing obligations |  |  | 1,836 |  |  |  | 1,135 |
Other |  |  | 4,809 |  |  |  | 5,563 |
Total deferred tax assets |  |  | 321,007 |  |  |  | 271,734 |
Deferred tax liabilities: |  |  |  |  |  |  |  |
Fixed assets |  |  | (607 | ) |  |  | (124 | )
Right of use asset |  |  | (1,527 | ) |  |  | (854 | )
Total deferred tax liabilities |  |  | (2,134 | ) |  |  | (978 | )
Valuation allowance |  |  | (318,714 | ) |  |  | (270,756 | )
Net deferred tax assets |  | $ | 159 |  |  | $ | − |
The majority of the Company’s deferred tax assets relate to net operating loss and research and development carryforwards that can only be realized if the Company is profitable in future periods. It is uncertain whether the Company will realize any tax benefit related to these carryforwards. Accordingly, the Company has provided a valuation allowance against substantially all the net deferred tax assets due to uncertainties as to their ultimate realization. The valuation allowance will remain at the full amount of the deferred tax assets until it is more likely than not that the related tax benefits will be realized. The Company’s valuation allowance increased by $47,954, $38,551, and $23,824 in 2021, 2020, and 2019, respectively. As of December 31, 2021, the Company had U.S. federal operating loss carryforwards of $480,331, state operating loss carryforwards of $177,567, foreign net operating losses of $29,355, and U.S. research and development and orphan drug credit carryforwards of $80,925, which will expire at various dates from 2022 through 2041. Federal losses, state losses, research and development credit carryforwards began expiring in 2020. The foreign net operating losses have an indefinite carryforward period. Tax years 2018-2021 remain open to examination by the major taxing jurisdictions to which the Company is subject. Additionally, years prior to 2017 are also open to examination to the extent of loss and credit carryforwards from those years. The Company recognizes interest and penalties accrued related to unrecognized tax benefits as components of its income tax provision. However, there were no provisions or accruals for interest and penalties in 2021, 2020 and 2019. As of December 31, 2021, the Company has accumulated undistributed earnings of $750, generated by our foreign subsidiaries which have already been subject to local and U.S. tax (as part of the GILTI provisions). We intend to indefinitely reinvest these earnings, as well as future earnings from our foreign subsidiaries to fund out international operations. In addition, we expect future U.S. cash generation will be sufficient to meet future U.S cash needs.

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 21 -URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 17 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 6.I.5.Q1) -URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 14 -URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 270 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -URI http://asc.fasb.org/topic&trid=2144680 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 + Details
Name: | us-gaap_IncomeTaxDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration